Henlius (2696.HK)

Recent Business Updates


© 2020 Henlius

Disclaimer

Henlius, the representor or the provider does not make any warranties, statements or representations, express or implied, on the content of this document (the content of this document may also include forward

© 2020 Henlius

Jointly promote commercialization of products with global strategic partners



HLX02

Trastuzumab) Entering the USA

Highlights of Henlius/Accord HLX02 Deal

(trastuzumab independently developed by Henlius) in the USA and Canada

Henlius will obtain upfront payment (US$27M), regulatory milestone payment (not more than US$13M) , sales milestone payment (US$25M for every US$500M of cumulative net sales), and royalty from 18% to 50% of the net profit

A successful entry into the North American market is a major milestone and a crucial step of globalization

About Accord

Accord is a global business of developing, manufacturing and marketing generic drugs and biosimilars in more than 70 nations including North America, Europe, Australia, and South Africa.

129 generic focusing on the hospital market with emphasis on oncology, central nervous system and other intensive care segments

-growing pharmaceutical companies in the **USA**, maintaining double-digit growth in

Licensor	Shanghai Henlius Biotech, Inc.
Licensee	Accord Healthcare Inc.
Effective Date	2020-09
Licensed Product	HLX02 (Trastuzumab injection) (150mg, 420mg, 60mg
Territory	The USA and Canada
License	Develop and commercialize HLX02 (Trastuzumab injection
Milestone Payment	


Source: company announcement

Globalization Strategy of Henlius


– Paradigm: China + Emerging Global

Biosimilar CHINA+Emerging Markets


Bioinnovative Leading CHINA, Fusion GLOBAL



One Belt One Road







© 2020 Henlius